September 14, 2012 – 4.19 pm
(ASCA) – Scoppito (L'Aquila), September 14 – The Government needs to take action to define rules capable of protecting the industrial property of medicines. This was explained by Daniel Lapeyre, president of Sanofi Italia, who this morning attended the ceremony for the 40th anniversary of the Sanofi plant in Scoppito.
"The company, the leading pharmaceutical industrial group in the country - he underlined - trusts that the Government will be able to give the pharmaceutical sector shared rules that protect industrial property, i.e. the patent and trademark of expired patent drugs, essential values for the patient and for industry in Italy, as well as guaranteeing access to therapeutic innovation. These are founding values for an industrial sector that has the patient at the heart of its reason for being and which represents, at the same time, an industrial excellence of our country, recognized at an international level”.
rus/sam/bra
DRUGS: SANOFI TURNS 40 YEARS OF EXCELLENCE AND INNOVATION
(AGI) - Scoppito (L'Aquila), 14 September. – Over 90 countries reached by drugs produced in Scoppito (L'Aquila), about 330 highly skilled collaborators, top-level production technologies. A successful present, destined to grow further in the future, thanks to the investments planned by the Sanofi Group, which sees in the Abruzzo plant a point of reference in its worldwide production network. To celebrate the 40th anniversary of the foundation of the facility, the top management of Sanofi and the institutions of Abruzzo met this morning at the site to take stock of the present and above all the future of one of the top manufacturing companies in the area. Behind the shoulders – it was underlined by the top management – the certainty of constant growth since 1972, marked by two keywords: excellence and innovation. Suffice it to say that in 2011 alone, 4.25 billion tablets were produced at the Sanofi production site in Scoppito for 120 million pharmaceutical packs, with exports worth 61.5 million euros, equal to 26 percent of Sanofi's exports to Italy. But the Sanofi pharmaceutical production site, which is celebrating the 40th anniversary of its foundation, above all has a paved road towards the future, always traced in the wake of innovation and excellence. Last year alone, 3.2 million euros were invested in production and another 26 have already been allocated for the next four years, with the aim of improving the already cutting-edge technological equipment of a structure destined to be increasingly crucial in the Group's production network.
investments,
